Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes .

Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease .

An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection.

The patients taking the drug were also less likely to die from cardiovascular disease — another condition that affects many patients with diabetes.

The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada’s decision.

Dr. David Cherney, a nephrolog

See Full Page